Evidence map›Paper›PMID 18460553›Full record

ArticleGut2008

Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus.

O Pech, A Behrens, A May, L Nachbar, L Gossner, T Rabenstein, H Manner, E Guenter, J Huijsmans, M Vieth and 2 more

2 registry-linked trialsAbstract readEvaluation Study
PubMed Publisher
In one paragraph

Article in Gut, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 213 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
213citing papers in PubMed, 7 pooled it
53.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01868139 naterminatednot on this mapstarted 2013, after this paper: background citation

A Phase II, Multi-Center Study of Interventional Spray Cryotherapy for Early-Stage Esophageal Cancer (ICE-CANCER)

TypeinterventionalSponsorUniversity of Maryland, BaltimoreRan2013 to 2014Enrolled1ConditionsEsophageal CancerArmsLiquid nitrogen spray cryotherapy with the truFreeze device
NCT05983419 naunknown statusnot on this mapstarted 2023, after this paper: background citation

Complete Resection of Barrett's Esophagus Harboring Neoplasia With Endoscopic Submucosal Dissection.

TypeinterventionalSponsorFrancisco Baldaque-SilvaRan2023 to 2026Enrolled40ConditionsBarretts Esophagus With DysplasiaArmsESD
3 · Its place in the literature

Who cites it

213 citing papers in PubMed, 7 syntheses or guidelines pooled it, 679 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus.The American journal of gastroenterology · 2016
    Guideline
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Endoscopic Screening of Barrett's Esophagus.Gastrointestinal endoscopy clinics of North America · 2026
    Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

153 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

O PechDepartment of Internal Medicine II, HSK Wiesbaden, Ludwig-Erhard-Strasse 100, 65199 Wiesbaden, Germany.
A Behrens
A May
L Nachbar
L Gossner
T Rabenstein
H Manner
E Guenter
J Huijsmans
M Vieth
M Stolte
C Ell
Helios Dr. Horst Schmidt Kliniken Wiesbaden · DEBayreuth Medical Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveEndoscopic therapy is increasingly being used in the treatment of high-grade intraepithelial neoplasia (HGIN) and mucosal adenocarcinoma (BC) in patients with Barrett's oesophagus. This report provides 5 year follow-up data from a large prospective study investigating the efficacy and safety of endoscopic treatment in these patients and analysing risk factors for recurrence.

designProspective case series.

settingAcademic tertiary care centre. PATIENTS: Between October 1996 and September 2002, 61 patients with HGIN and 288 with BC were included (173 with short-segment and 176 with long-segment Barrett's oesophagus) from a total of 486 patients presenting with Barrett's neoplasia. Patients with submucosal or more advanced cancer were excluded.

interventionsEndoscopic therapy.

main outcome measuresRate of complete remission and recurrence rate, tumour-associated death.

resultsEndoscopic resection was performed in 279 patients, photodynamic therapy in 55, and both procedures in 13; two patients received argon plasma coagulation. The mean follow-up period was 63.6 (SD 23.1) months. Complete response (CR) was achieved in 337 patients (96.6%); surgery was necessary in 13 (3.7%) after endoscopic therapy failed. Metachronous lesions developed during the follow-up in 74 patients (21.5%); 56 died of concomitant disease, but none died of BC. The calculated 5 year survival rate was 84%. The risk factors most frequently associated with recurrence were piecemeal resection, long-segment Barrett's oesophagus, no ablative therapy of Barrett's oesophagus after CR, time until CR achieved >10 months and multifocal neoplasia.

conclusionsThis study showed that endoscopic therapy was highly effective and safe, with an excellent long-term survival rate. The risk factors identified may help stratify patients who are at risk for recurrence and those requiring more intensified follow-up.

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overBarrett EsophagusCarcinoma in SituEpidemiologic MethodsEsophageal NeoplasmsEsophagoscopyFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPrecancerous Conditions

Identifiers

PMID18460553
OpenAlexW1984060133

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.